Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30. https://doi.org/10.3322/caac.21590.
Article
PubMed
Google Scholar
Ducreux M, Cuhna AS, Caramella C, Hollebecque A, Burtin P, Goere D, et al. Cancer of the pancreas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Suppl 5):v56–68. https://doi.org/10.1093/annonc/mdv295.
Article
PubMed
Google Scholar
Sohal DPS, Kennedy EB, Khorana A, Copur MS, Crane CH, Garrido-Laguna I, et al. Metastatic Pancreatic Cancer: ASCO Clinical Practice Guideline Update. J Clin Oncol. 2018;36(24):2545–56. https://doi.org/10.1200/JCO.2018.78.9636.
Article
PubMed
Google Scholar
Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18):1691–703. https://doi.org/10.1056/NEJMoa1304369.
Article
CAS
Google Scholar
Kang J, Hwang I, Yoo C, Kim KP, Jeong JH, Chang HM, et al. Nab-paclitaxel plus gemcitabine versus FOLFIRINOX as the first-line chemotherapy for patients with metastatic pancreatic cancer: retrospective analysis. Investig New Drugs. 2018;36(4):732–41. https://doi.org/10.1007/s10637-018-0598-5.
Article
CAS
Google Scholar
Peixoto RD, Ho M, Renouf DJ, Lim HJ, Gill S, Ruan JY, et al. Eligibility of metastatic pancreatic Cancer patients for first-line palliative intent nab-paclitaxel plus gemcitabine versus FOLFIRINOX. Am J Clin Oncol. 2017;40(5):507–11. https://doi.org/10.1097/COC.0000000000000193.
Article
CAS
PubMed
Google Scholar
Kang H, Jo JH, Lee HS, Chung MJ, Bang S, Park SW, et al. Comparison of efficacy and safety between standard-dose and modified-dose FOLFIRINOX as a first-line treatment of pancreatic cancer. World J Gastrointest Oncol. 2018;10(11):421–30. https://doi.org/10.4251/wjgo.v10.i11.421.
Article
PubMed
PubMed Central
Google Scholar
Tong H, Fan Z, Liu B, Lu T. The benefits of modified FOLFIRINOX for advanced pancreatic cancer and its induced adverse events: a systematic review and meta-analysis. Sci Rep. 2018;8(1):8666. https://doi.org/10.1038/s41598-018-26811-9.
Article
CAS
PubMed
PubMed Central
Google Scholar
Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817–25. https://doi.org/10.1056/NEJMoa1011923.
Article
CAS
PubMed
Google Scholar
Kiefer C, Sturtz S, Bender R. Indirect comparisons and network meta-analyses. Dtsch Arztebl Int. 2015;112(47):803–8. https://doi.org/10.3238/arztebl.2015.0803.
Article
PubMed
PubMed Central
Google Scholar
Kim H, Gurrin L, Ademi Z, Liew D. Overview of methods for comparing the efficacies of drugs in the absence of head-to-head clinical trial data. Br J Clin Pharmacol. 2014;77(1):116–21. https://doi.org/10.1111/bcp.12150.
Article
CAS
PubMed
Google Scholar
Donegan S, Williamson P, D'Alessandro U, Tudur Smith C. Assessing key assumptions of network meta-analysis: a review of methods. Res Synth Methods. 2013;4(4):291–323. https://doi.org/10.1002/jrsm.1085.
Article
PubMed
Google Scholar
Salanti G. Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool. Res Synth Methods. 2012;3(2):80–97. https://doi.org/10.1002/jrsm.1037.
Article
PubMed
Google Scholar
White IR, Barrett JK, Jackson D, Higgins JP. Consistency and inconsistency in network meta-analysis: model estimation using multivariate meta-regression. Res Synth Methods. 2012;3(2):111–25. https://doi.org/10.1002/jrsm.1045.
Article
PubMed
PubMed Central
Google Scholar
Chaimani A, Higgins JP, Mavridis D, Spyridonos P, Salanti G. Graphical tools for network meta-analysis in STATA. PLoS One. 2013;8(10):e76654. https://doi.org/10.1371/journal.pone.0076654.
Article
CAS
PubMed
PubMed Central
Google Scholar
White I. MVMETA: Stata module to perform multivariate random-effects meta-analysis. Available at: https://econpapers.repec.org/software/bocbocode/s456970.htm. Accessed May 2020.
White IR. Multivariate random-effects meta-regression: updates to mvmeta. Stata J. 2011;11(2):255–70. https://doi.org/10.1177/1536867X1101100206.
Article
Google Scholar
Dias S, Welton NJ, Caldwell DM, Ades AE. Checking consistency in mixed treatment comparison meta-analysis. Stat Med. 2010;29(7–8):932–44. https://doi.org/10.1002/sim.3767.
Article
CAS
PubMed
Google Scholar
Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA. Cochrane handbook for systematic reviews of interventions. Available at: https://onlinelibrary.wiley.com/doi/book/10.1002/9781119536604. Accessed May 2020.
Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629–34. https://doi.org/10.1136/bmj.315.7109.629.
Article
CAS
PubMed
PubMed Central
Google Scholar
Barrera I, Ranger J, Roofigari N, Dalfen R, Batist G, Kavan P. Treatment sequencing in MPC, insights from a 3° care center. J Clin Oncol. 2019;37(4_suppl):400. https://doi.org/10.1200/JCO.2019.37.4_suppl.400.
Article
Google Scholar
Chan KKW, Guo H, Cheng S, Beca JM, Redmond-Misner R, Isaranuwatchai W, et al. Real-world outcomes of FOLFIRINOX vs gemcitabine and nab-paclitaxel in advanced pancreatic cancer: a population-based propensity score-weighted analysis. Cancer Med. 2020;9(1):160–9. https://doi.org/10.1002/cam4.2705.
Article
CAS
PubMed
Google Scholar
Cho I, Kang H, Jo J, Lee H, Chung M, Park J, et al. FOLFIRINOX versus gemcitabine plus nab-paclitaxel for treatment of metastatic pancreatic cancer: a single-center cohort study. Ann Oncol. 2018;29:v45. https://doi.org/10.1093/annonc/mdy151.160.
Article
Google Scholar
de Jesus VHF, Camandaroba MPG, Donadio MDS, Cabral A, Muniz TP, de Moura LL, et al. Retrospective comparison of the efficacy and the toxicity of standard and modified FOLFIRINOX regimens in patients with metastatic pancreatic adenocarcinoma. J Gastrointest Oncol. 2018;9(4):694–707. https://doi.org/10.21037/jgo.2018.04.02.
Article
PubMed
PubMed Central
Google Scholar
Javed MA, Beyer G, Le N, Vinci A, Wong H, Palmer D, et al. Impact of intensified chemotherapy in metastatic pancreatic ductal adenocarcinoma (PDAC) in clinical routine in Europe. Pancreatology. 2019;19(1):97–104. https://doi.org/10.1016/j.pan.2018.10.003.
Article
CAS
PubMed
Google Scholar
Kang H, Jo JH, Lee HS, Chung MJ, Bang S, Park SW, et al. Comparison of efficacy and safety between standard-dose and modified-dose FOLFIRINOX as a first-line treatment of pancreatic cancer. World Journal of Gastrointestinal Oncology. 2018;10(11):421–30. https://doi.org/10.4251/wjgo.v10.i11.421.
Article
PubMed
PubMed Central
Google Scholar
Kang J, Hwang I, Yoo C, Kim K-P, Jeong JH, Chang H-M, et al. nab-paclitaxel plus gemcitabine versus FOLFIRINOX as the first-line chemotherapy for patients with metastatic pancreatic cancer: retrospective analysis. Investig New Drugs. 2018;36(4):732–41. https://doi.org/10.1007/s10637-018-0598-5.
Article
CAS
Google Scholar
Kasi A, Middinti A, Cao A, Vekaria P, Patel D, Subramaniam D, et al. FOLFIRINOX versus gemcitabine nab-paclitaxel for advanced pancreatic cancer: KU Cancer center experience. J Clin Oncol. 2017;35(15_suppl):e15744. https://doi.org/10.1200/JCO.2017.35.15_suppl.e15744.
Article
Google Scholar
Kim S, Signorovitch JE, Yang H, Patterson-Lomba O, Xiang CQ, Ung B, et al. Comparative effectiveness of nab-paclitaxel plus gemcitabine vs FOLFIRINOX in metastatic pancreatic Cancer: a retrospective Nationwide chart review in the United States. Adv Ther. 2018;35(10):1564–77. https://doi.org/10.1007/s12325-018-0784-z.
Article
CAS
PubMed
PubMed Central
Google Scholar
Latenstein AEJ, Mackay TM, Creemers GJ, van Eijck CHJ, de Groot JWB, Haj Mohammad N, et al. Implementation of contemporary chemotherapy for patients with metastatic pancreatic ductal adenocarcinoma: a population-based analysis. Acta Oncol. 2020;59(6):705-12. https://doi.org/10.1080/0284186X.2020.1725241.
Lee J-C, Shin DW, Yang SY, Kim MJ, Kim J, Woo SM, Lee WJ, Choi KS, Jung JH, Kang J, et al. Comparison of FOLFIRINOX and gemcitabine with nab-paclitaxel in metastatic pancreatic cancer: Using Korean Pancreatic Cancer (K-PaC) Registry. J Clin Oncol. 2019;37(15). online only.
Longo Muñoz F, Castillo Trujillo O, Serrano Domingo J, Martín Huertas R, Corral De La Fuente E, San Juan A, et al. Folfirinox versus nab-paclitaxel plus gemcitabine in the first-line chemotherapy for patients with advanced pancreatic ductal adenocarcinoma: A multivariate analysis of prognostic factors in a national cohort (Comunica-TTD working group). Ann Oncol. 2019;30:aa92–3.
Article
Google Scholar
Muranaka T, Kuwatani M, Komatsu Y, Sawada K, Nakatsumi H, Kawamoto Y, et al. Comparison of efficacy and toxicity of FOLFIRINOX and gemcitabine with nab-paclitaxel in unresectable pancreatic cancer. Journal of Gastrointestinal Oncology. 2017;8(3):566–71. https://doi.org/10.21037/jgo.2017.02.02.
Article
PubMed
PubMed Central
Google Scholar
Nakazawa J, Otsuka T, Shimokawa M, Koga F, Ueda Y, Otsu S, et al. A multicenter retrospective study of gemcitabine plus nabpaclitaxel or FOLFIRINOX in metastatic pancreatic cancer: NAPOLEON study. Ann Oncol. 2019;30:aa17–8.
Article
Google Scholar
Ohba A, Ueno H, Sakamoto Y, Kondo S, Morizane C, Okusaka T. Retrospective comparison of modified FOLFIRINOX with full-dose FOLFIRINOX for advanced pancreatic cancer: A Japanese cancer center experience. J Clin Oncol. 2018;36(4):469.
Papneja N, Zaidi A, Chalchal H, Moser M, Tan K, Olson C, et al. Comparisons of outcomes of real-world patients with advanced pancreatic Cancer treated with FOLFIRINOX versus gemcitabine and nab-paclitaxel a population-based cohort study. Pancreas. 2019;48(7):920–6. https://doi.org/10.1097/MPA.0000000000001340.
Article
CAS
PubMed
Google Scholar
Tahara J, Shimizu K, Otsuka N, Akao J, Takayama Y, Tokushige K. Gemcitabine plus nab-paclitaxel vs. FOLFIRINOX for patients with advanced pancreatic cancer. Cancer Chemother Pharmacol. 2018;82(2):245–50. https://doi.org/10.1007/s00280-018-3611-y.
Article
CAS
PubMed
Google Scholar
Terashima T, Yamashita T, Sakai A, Ohta H, Hinoue Y, Toya D, et al. Treatment patterns and outcomes of unresectable pancreatic cancer patients in real-life practice: a region-wide analysis. Jpn J Clin Oncol. 2018;48(11):966–73. https://doi.org/10.1093/jjco/hyy132.
Article
PubMed
Google Scholar
Vienot A, Chevalier H, Bolognini C, Gherga E, Klajer E, Meurisse A, et al. FOLFOXIRI vs FOLFIRINOX as first-line chemotherapy in patients with advanced pancreatic cancer: a population-based cohort study. World J Gastrointest Oncol. 2020;12(3):332–46. https://doi.org/10.4251/wjgo.v12.i3.332.
Article
PubMed
PubMed Central
Google Scholar
Wang Y, Camateros P, Cheung WY. A real-world comparison of FOLFIRINOX, gemcitabine plus nab-paclitaxel, and gemcitabine in advanced pancreatic cancers. J Gastrointest Cancer. 2019;50(1):62–8. https://doi.org/10.1007/s12029-017-0028-5.
Article
CAS
PubMed
Google Scholar
Watanabe K, Hashimoto Y, Umemoto K, Takahashi H, Sasaki M, Imaoka H, Ohno I, Mitsunaga S, Ikeda M. Clinical outcome of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel as first line chemotherapy in metastatic pancreatic cancer. J Clin Oncol. 2017;35(4):438.
Williet N, Saint A, Pointet AL, Tougeron D, Pernot S, Pozet A, et al. Folfirinox versus gemcitabine/nab-paclitaxel as first-line therapy in patients with metastatic pancreatic cancer: a comparative propensity score study. Ther Adv Gastroenterol. 2019;12:1756284819878660.
Article
Google Scholar
Pusceddu S, Ghidini M, Torchio M, Corti F, Tomasello G, Niger M, Prinzi N, Nichetti F, Coinu A, Di Bartolomeo M, et al. Comparative Effectiveness of Gemcitabine plus Nab-Paclitaxel and FOLFIRINOX in the First-Line Setting of Metastatic Pancreatic Cancer: A Systematic Review and Meta-Analysis. Cancers (Basel). 2019;11(4):484.
Ducreux M, Mitry E, Ould-Kaci M, Boige V, Seitz JF, Bugat R, et al. Randomized phase II study evaluating oxaliplatin alone, oxaliplatin combined with infusional 5-FU, and infusional 5-FU alone in advanced pancreatic carcinoma patients. Ann Oncol. 2004;15(3):467–73. https://doi.org/10.1093/annonc/mdh098.
Article
CAS
PubMed
Google Scholar
Conroy T, Paillot B, Francois E, Bugat R, Jacob JH, Stein U, et al. Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancer--a Groupe Tumeurs digestives of the federation Nationale des Centres de Lutte Contre le Cancer study. J Clin Oncol. 2005;23(6):1228–36. https://doi.org/10.1200/JCO.2005.06.050.
Article
CAS
PubMed
Google Scholar
Gourgou-Bourgade S, Bascoul-Mollevi C, Desseigne F, Ychou M, Bouche O, Guimbaud R, et al. Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial. J Clin Oncol. 2013;31(1):23–9. https://doi.org/10.1200/JCO.2012.44.4869.
Article
CAS
PubMed
Google Scholar
Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15(6):2403–13. https://doi.org/10.1200/JCO.1997.15.6.2403.
Article
CAS
PubMed
Google Scholar
Souglakos J, Androulakis N, Syrigos K, Polyzos A, Ziras N, Athanasiadis A, et al. FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic oncology research group (HORG). Br J Cancer. 2006;94(6):798–805. https://doi.org/10.1038/sj.bjc.6603011.
Article
CAS
PubMed
PubMed Central
Google Scholar
Vivaldi C, Caparello C, Musettini G, Pasquini G, Catanese S, Fornaro L, et al. First-line treatment with FOLFOXIRI for advanced pancreatic cancer in clinical practice: Patients' outcome and analysis of prognostic factors. Int J Cancer. 2016;139(4):938–45. https://doi.org/10.1002/ijc.30125.
Article
CAS
PubMed
Google Scholar
Gresham GK, Wells GA, Gill S, Cameron C, Jonker DJ. Chemotherapy regimens for advanced pancreatic cancer: a systematic review and network meta-analysis. BMC Cancer. 2014;14(1):471. https://doi.org/10.1186/1471-2407-14-471.
Article
CAS
PubMed
PubMed Central
Google Scholar
Ghorani E, Wong HH, Hewitt C, Calder J, Corrie P, Basu B. Safety and efficacy of modified FOLFIRINOX for advanced pancreatic adenocarcinoma: a UK single-Centre experience. Oncology. 2015;89(5):281–7. https://doi.org/10.1159/000439171.
Article
CAS
PubMed
Google Scholar
Stein SM, James ES, Deng Y, Cong X, Kortmansky JS, Li J, et al. Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer. Br J Cancer. 2016;114(7):737–43. https://doi.org/10.1038/bjc.2016.45.
Article
CAS
PubMed
Google Scholar
McBride A, Bonafede M, Cai Q, Princic N, Tran O, Pelletier C, et al. Comparison of treatment patterns and economic outcomes among metastatic pancreatic cancer patients initiated on nab-paclitaxel plus gemcitabine versus FOLFIRINOX. Expert Rev Clin Pharmacol. 2017;10(10):1153–60. https://doi.org/10.1080/17512433.2017.1365598.
Article
CAS
PubMed
Google Scholar
Kim GP, Parisi MF, Patel MB, Pelletier CL, Belk KW. Comparison of treatment patterns, resource utilization, and cost of care in patients with metastatic pancreatic cancer treated with first-line nab-paclitaxel plus gemcitabine or FOLFIRINOX. Expert Rev Clin Pharmacol. 2017;10(5):559–65. https://doi.org/10.1080/17512433.2017.1302330.
Article
CAS
PubMed
Google Scholar
Sohal DPS, Duong M, Ahmad SA, Gandhi NS, Beg MS, Wang-Gillam A, et al. Efficacy of perioperative chemotherapy for Resectable pancreatic adenocarcinoma: a phase 2 randomized clinical trial. JAMA Oncol. 2021;7(3):421–7. https://doi.org/10.1001/jamaoncol.2020.7328.
Article
PubMed
Google Scholar